Jaguar Health, Inc. Files 8-K: Announces Return to Nasdaq Compliance on Stockholders’ Equity

San Francisco, April 9, 2026 – Jaguar Health, Inc. (Nasdaq: JAGX), a pharmaceutical company focusing on developing novel, plant-based prescription medicines, has filed a Form 8-K with the Securities and Exchange Commission (SEC) to announce a significant update regarding its compliance with Nasdaq listing requirements.

Key Highlights from the Report

• Stockholders’ Equity Issue Previously Disclosed: As of December 31, 2025, Jaguar Health reported a total stockholders’ deficit of approximately \$18.7 million. This deficit placed the company out of compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of \$2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market.
• Actions Taken to Restore Compliance: Since the end of 2025, Jaguar Health has taken various actions which, the company believes, restored its stockholders’ equity above the required threshold. These actions include:
  • Receiving \$16.0 million in non-dilutive capital under a license agreement with Napo Pharmaceuticals, Inc. (a Jaguar subsidiary), Woodward Specialty LLC, and Future Pak, LLC, dated January 12, 2026.
  • Receiving additional payments related to Mytesi product sales and supply agreements, totaling several hundred thousand dollars.
  • Recognition of approximately \$0.2 million in grant revenue.
  • A gain of roughly \$3.4 million from the extinguishment of certain debts owed to affiliates of Chicago Venture Partners, L.P.
• Stockholders’ Equity Exceeds Nasdaq Requirement: As of April 7, 2026, taking into account all the above factors, the company’s stockholders’ equity exceeded \$2.5 million. This means Jaguar Health now believes it has regained compliance with the Nasdaq listing rule.

Key Information for Shareholders

• Nasdaq Listing at Stake: Non-compliance with Nasdaq’s equity requirement could have led to delisting, a major risk for shareholders. The company’s actions to restore compliance reduce this risk and should be viewed as a positive development.
• Capital Structure and Non-Dilutive Capital: The \$16.0 million capital injection was non-dilutive, meaning it did not involve issuing new shares or diluting existing shareholders. This is a favorable outcome for investors concerned about dilution.
• Debt Reduction: The company’s gain from extinguishing part of its debts directly improves its balance sheet health, reducing financial risk and interest expenses going forward.
• Revenue Streams and Partnerships: The license and supply agreements generating the capital inflows and product sales indicate that Jaguar Health is leveraging its assets and partnerships to improve financial stability.

Potential Impact on Share Price

The restoration of compliance with Nasdaq’s equity requirement is a material event for shareholders. Maintaining a Nasdaq listing supports liquidity, institutional investment, and market confidence. The use of non-dilutive capital and debt reduction further enhance the financial outlook and may positively influence investor sentiment and the share price.

However, it is important to note that the company’s statements regarding compliance are based on “forward-looking statements” and management’s beliefs. Actual outcomes may differ, and the company cautions investors not to place undue reliance on forward-looking statements.

Management Statement

The Form 8-K was signed by Lisa A. Conte, Chief Executive Officer and President of Jaguar Health, Inc., on April 9, 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should carefully review the company’s filings and consult their financial advisors before making investment decisions. Past performance is not indicative of future results.

View Jaguar Health, Inc. Historical chart here